PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

December 20, 2022

Study Completion Date

January 6, 2023

Conditions
Alzheimer DiseaseDementia
Interventions
DRUG

Normal Saline along with standard treatment

PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.

DRUG

PMZ-1620 (sovateltide) along with standard treatment

PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.

Trial Locations (5)

110029

All India Institute of Medical Sciences, New Delhi

160012

Post Graduate Institute of Medical Education and Research, Chandigarh

226003

King George's Medical University, Lucknow

226014

Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow

400012

Seth GSMC & KEM Hospital, Mumbai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmazz, Inc.

INDUSTRY

NCT04052737 - PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter